相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
Rachel N. Grisham et al.
CANCER (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR)
Sabine Heublein et al.
JOURNAL OF OVARIAN RESEARCH (2013)
Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer
Thore Hillig et al.
APMIS (2012)
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor
A. Bamias et al.
EUROPEAN JOURNAL OF CANCER (2012)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
Jaime Prat
VIRCHOWS ARCHIV (2012)
Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
Aphrothiti J. Hanrahan et al.
CANCER DISCOVERY (2012)
The role of PARP1 in the DNA damage response and its application in tumor therapy
Zhifeng Wang et al.
Frontiers of Medicine (2012)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Advanced Stage Mucinous Adenocarcinoma of the Ovary Is Both Rare and Highly Lethal A Gynecologic Oncology Group Study
Richard J. Zaino et al.
CANCER (2011)
PARP Inhibitor Treatment in Ovarian and Breast Cancer
[Anonymous]
CURRENT PROBLEMS IN CANCER (2011)
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm
Robert J. Kurman et al.
HUMAN PATHOLOGY (2011)
Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
Jonathan A. Ledermann et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors
Ildiko Vereczkey et al.
PATHOLOGY & ONCOLOGY RESEARCH (2011)
BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas
Kwong-Kwok Wong et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible A Transcanadian Study
Martin Koebel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience
J. Alexandre et al.
ANNALS OF ONCOLOGY (2010)
The Molecular Pathogenesis of Hereditary Ovarian Carcinoma
Barbara M. Norquist et al.
CANCER (2010)
Gene Amplification CCNE1 Is Related to Poor Survival and Potential Therapeutic Target in Ovarian Cancer
Naomi Nakayama et al.
CANCER (2010)
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers
Katrin Kristjansdottir et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer
Emir Senturk et al.
GYNECOLOGIC ONCOLOGY (2010)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ashour Ahmed Ahmed et al.
JOURNAL OF PATHOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Cécile Le Page et al.
Cancers (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cystic and Adenofibromatous Clear Cell Carcinomas of the Ovary Distinctive Tumors That Differ in Their Pathogenesis and Behavior: A Clinicopothologic Analysis of 122 Cases
Emanuela Veras et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas A Clinicopathologic and Molecular Genetic Analysis
Ayse Ayhan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Nathan T. Ihle et al.
CANCER RESEARCH (2009)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Ovarian Epithelial Dysplasia and Prophylactic Oophorectomy for Genetic Risk
Gautier Chene et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of Disease Endometriosis
Serdar E. Bulun
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary
Martin Köbel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007
Gordon F. Schwartz et al.
CANCER (2008)
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
C. Blake Gilks et al.
HUMAN PATHOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Primary Fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
Michael J. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Meta-analysis of BRCA1 and BRCA2 penetrance
Sining Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
David W. Kindelberger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Y. Lee et al.
JOURNAL OF PATHOLOGY (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)
J. A. Green et al.
EUROPEAN JOURNAL OF CANCER (2006)
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging
M. Takano et al.
BRITISH JOURNAL OF CANCER (2006)
Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer
A Schmider-Ross et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome
F Medeiros et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis
William D. Foulkes
FAMILIAL CANCER (2006)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma
MR Raspollini et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2005)
RAS is regulated by the let-7 MicroRNA family
SM Johnson et al.
CELL (2005)
HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance - Clinical study
E Verri et al.
ONCOLOGY (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer
A Bali et al.
CLINICAL CANCER RESEARCH (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers
ML Carcangiu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis
JMJ Piek et al.
GYNECOLOGIC ONCOLOGY (2003)
Role of cell-cycle regulatory proteins in gynecological cancer
K Milde-Langosch et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cancer susceptibility and the functions of BRCA1 and BRCA2
AR Venkitaraman
CELL (2002)
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
JMJ Piek et al.
JOURNAL OF PATHOLOGY (2001)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
MJ Piccart et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
FM Muggia et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
